Charts

One is a well-established, large-cap drugmaker, while the other is still making a name for itself in the industry.

Over the past 3 months, 11 analysts have published their opinion on Axsome Therapeutics (NASDAQ:AXSM) stock. These analysts are ...

There are no guarantees that any stock will generate huge returns. But the odds look pretty good for these three growth stocks.

The collapse of SVB will leave early-stage biotech companies in a funding dearth. But big-name biotech stocks will emerge largely untouched.

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares US.

These three Nasdaq stocks are poised to make big moves in the coming week.

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2022 Earnings Call Transcript February 27, 2023 Operator: Good morning, and welcome to the Axsome Therapeutics Conference Call. Currently, all participants are in listen-only mode. Later, there will be a question-and-answer session, and instructions will follow at that time. As a reminder, today’s conference is being recorded. I would now […]

The biotech made major progress on the regulatory front last year.

These five businesses are worth a look for patient investors.

Axsome Therapeutics (NASDAQ:AXSM) brought in sales totaling $24.37 million during Q4 according to data provided by Benzinga Pro. ...

Analysts have provided the following ratings for Axsome Therapeutics (NASDAQ:AXSM) within the last quarter: Bullish Somewhat ...

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in a fireside chat at Cowen’s 43rd Annual Health Care Conference on Wednesday, March 8, 2023, at 2:10 p.m. Eastern Time at the Boston Marriott Copley Place. A live webcast and archive of

Axsome Therapeutics (AXSM) incurs wider-than-expected loss in Q4 2022. Revenues beat estimates while shares gain.

Q4 2022 Axsome Therapeutics Inc Earnings Call

AXSM earnings call for the period ending December 31, 2022.

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Axsome Therapeutics Inc (AXSM), where a total volume of 5,904 contracts has been traded thus far today, a contract volume which is representative of approximately 590,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 62.8% of AXSM's average daily trading volume over the past month, of 940,115 shares..

Axsome Therapeutics Inc (NASDAQ: AXSM)shares are trading higher by 3.22% to $63.02Monday morning after the company reported ...

Total fourth quarter net product sales of $24.4 million Auvelity® launched October 19th, with fourth quarter net product sales of $5.2 million Sunosi® fourth quarter net product sales of $19.2 million Sunosi® license agreement for EU announced – $66 million upfront, potential milestones up to $101 million Pro forma fourth quarter net cash in excess of $300 million Company to host conference call today at 8:00 AM Eastern NEW YORK, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDA

All three of these stocks have impressive growth prospects.

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on ...

Axsome Therapeutics (NASDAQ:AXSM) is set to give its latest quarterly earnings report on Monday, 2023-02-27. Here's what investors need ...

Axsome to receive an upfront payment of $66 million, and is eligible to receive sales-based and other milestones totaling up to $101 million Pharmanovia is responsible for all ongoing and future clinical studies in Europe and MENA NEW YORK, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it has entered into an exclusi

San Diego, CA -- (SBWIRE) -- 02/17/2023 -- An investor in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) filed a lawsuit against certain directors of Axsome Therapeutics, Inc. over alleged breaches of fiduciary duties.

With the business potentially at an important milestone, we thought we'd take a closer look at Axsome Therapeutics...

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Iron Mountain Inc (IRM), where a total of 7,540 contracts have traded so far, representing approximately 754,000 underlying shares. That amounts to about 46.6% of IRM's average daily trading volume over the past month of 1.6 million shares..

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Meta Platforms (META) layoffs are a hot topic among traders Monday as the Facebook parent company reportedly considering more job cuts. The post Meta Platforms Layoffs 2023: What to Know as Facebook Preps More Job Cuts appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Axsome Therapeutics (AXSM) stock is taking a beating on Monday as rival Teva Pharmaceutical (TEVA) prepares a generic depression drug. The post Axsome Therapeutics (AXSM) Stock Falls as Teva Pursues Generic Depression Drug appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It

Teva Pharmaceutical said Monday it plans to make a knockoff of Axsome Therapeutics' new depression treatment, leading AXSM stock to tumble.

Gainers Clene (NASDAQ:CLNN) stock increased by 51.9% to $2.05 during Monday's pre-market session. The company's market cap stands at ...

MARKET PULSE Shares of Axsome Therapeutics Inc. (AXSM) tumbled about 10.0% in premarket trading on Monday after the company said in a securities filing that Teva Pharmaceutical Industries Ltd. (TEVA) is seeking approval from the Food and Drug Administration to market a generic version of Auvelity, Axsome’s depression treatment.

These companies could grow in prominence in the coming years.

Maybe there's no such thing as a sure thing. But these stocks could come close.

These stocks could enjoy their own bull markets regardless of what the overall market does.

NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Wednesday, Feb. 15, 2023, at 8:40 a.m. Eastern Time. A live webcast and archive of the event can be viewed on the “W

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in United States Steel Corp. (X), where a total of 62,807 contracts have traded so far, representing approximately 6.3 million underlying shares..

Axsome to host conference call and webcast on Monday, Feb. 27, 2023, at 8:00 a.m. ETNEW YORK, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the fourth quarter and full year of 2022 on Monday, Feb. 27, 2023, before the opening of the U.S. financial markets. Axsome’s management

Analysts have provided the following ratings for Axsome Therapeutics (NASDAQ:AXSM) within the last quarter: Bullish Somewhat ...

These three companies should deliver inflation-busting long-term growth.

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Axsome Therapeutics Inc (AXSM) was identified as having a larger market cap than the smaller end of the S&P 500, for example Bio-Techne Corp (TECH), according to The Online Investor. Click here to find out the top S&P 500 components ordered by average analyst rating » Market capitalization is an important data point for investors to keep an eye on, for various reasons..

Investors in Axsome Therapeutics Inc (AXSM) saw new options begin trading today, for the April 21st expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 88 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

These stocks have plenty of room to run.

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Riot Platforms Inc (RIOT), where a total of 80,220 contracts have traded so far, representing approximately 8.0 million underlying shares. That amounts to about 57.6% of RIOT's average daily trading volume over the past month of 13.9 million shares..

These companies have what it takes to drive long-term share performance.

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Axsome Therapeutics Inc (AXSM), where a total of 5,742 contracts have traded so far, representing approximately 574,200 underlying shares. That amounts to about 60.7% of AXSM's average daily trading volume over the past month of 946,005 shares..

Axsome Therapeutics (NASDAQ:AXSM) has outperformed the market over the past 5 years by 73.66% on an annualized basis producing an ...

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P Pharmaceuticals ETF (XPH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $57.10 per unit.

These biotechs could crush the market, but there is more to the story.

These stocks look cheap if you take a long-term view.

Upgrades For Algonquin Power & Utilities Corp (NYSE:AQN), Wells Fargo upgraded the previous rating of Equal-Weight to Overweight. In ...

This may be the easiest of your New Year's resolutions. And it could pay off big.

Axsome Therapeutics's (NASDAQ:AXSM) short percent of float has fallen 7.06% since its last report. The company recently reported ...

These biotechs are far from having achieved their full potential.

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we ...

These mid-cap biotechs are solid long-term choices.

Axsome Therapeutics (NASDAQ:AXSM) has outperformed the market over the past 5 years by 62.16% on an annualized basis producing an ...

Investors in Axsome Therapeutics Inc (AXSM) saw new options begin trading today, for the February 2023 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AXSM options chain for the new February 2023 contracts and identified one put and one call contract of particular interest.

These businesses are growing and can be excellent places to make a sizable investment right now.

Revenue prospects look promising for both of these biotech companies.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Some of the hottest biotech stocks are safe and recession-proof. After all, we can’t stop people from aging – at least, not yet. We can’t stop people from seeking treatments for a myriad of issues. Plus, there’s growing demand for innovation in gene therapies, immune-oncology, precision medicine, machine-learning drug discovery, and treatments for unmet medical.... The post The 7 Hottest Biotech Stocks to Own in 2023 and Beyond appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

Stocks usually go down during recessions, but long-term investors can still come out on top.